IPO - SeaStar Medical Holding Corp

Form Type: S-1/A

Filing Date: 2025-06-20

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025055807

Filing Summary: SeaStar Medical Holding Corporation is conducting an amendment to its initial registration statement as it prepares for an initial public offering (IPO) under the Securities Act. The company is offering up to 5,149,860 shares of common stock alongside accompanying Series A and B warrants to purchase the same amount of common stock. The offering price is set at $0.9709 per share, reflecting the last closing price of its common stock on the Nasdaq. The company also mentions the option to sell pre-funded warrants to prevent any adverse ownership limitations. The pre-funded warrants have a minimal exercise price of $0.001 per share, and they will be sold alongside the same series of warrants. The offering is planned to conclude by July 18, 2025, unless terminated earlier. The decision to continue the offering is partly due to conditions imposed by Nasdaq related to maintaining a market value of listed securities and stockholders’ equity. This IPO aims to raise capital to enhance the company’s business in developing its Selective Cytopheretic Device (SCD), which is already FDA approved for pediatric patients with acute kidney injury.

Form Type: S-1

Filing Date: 2025-06-16

Corporate Action: Ipo

Type: New

Accession Number: 000121390025054502

Filing Summary: SeaStar Medical Holding Corporation is registering for an initial public offering of up to 4,237,288 shares of common stock along with accompanying warrants to purchase up to the same number of shares. The offering will commence following the effective date of the registration statement. Each share of common stock will have a public offering price of $1.18, based on the latest reported sale price. The company is also offering up to 4,237,288 pre-funded warrants for purchasers who would own more than 4.99% of the company after this offering, with an exercise price of $0.001 per share. The prospectus details the company's innovative Selective Cytopheretic Device (SCD) aimed at treating organ failure, especially acute kidney injury. The SCD is the only FDA approved device of its kind for pediatric patients and has obtained Breakthrough Device Designation for multiple indications, signaling fast-tracked potential approvals. The company is classified as a smaller reporting and emerging growth company, suggesting it will follow reduced reporting requirements. There are high-risk factors associated with this investment, including the potential need for future funding and the unestablished trading market for the offered securities. The overall business strategy and intended use of proceeds focus on advancing the development and commercialization of various therapeutic applications of the SCD technology. Additionally, the merger with LMAO was completed in late 2022, and the company is actively exploring expansions in treatment capabilities using its proprietary technology platform to address various inflammatory diseases, underlining the strategic milestones achieved.

Form Type: S-1

Filing Date: 2025-05-19

Corporate Action: Ipo

Type: New

Accession Number: 000121390025045463

Filing Summary: SeaStar Medical Holding Corporation has filed a Form S-1 registration statement with the SEC, indicating a significant milestone for the company as it seeks to raise capital through an IPO. The registration statement covers the proposed resale of up to 4,736,406 shares of its common stock by Lincoln Park Capital, which purchased shares under a Purchase Agreement dated April 25, 2025. The offering is aimed at raising up to $15 million in gross proceeds. The document specifies that SeaStar is not selling any shares directly and will not receive proceeds from the stock sale, highlighting the financial structure of this offering. The company specializes in developing medical therapies aimed at treating critically ill patients, particularly focusing on its Selective Cytopheretic Device (SCD) that has received FDA approvals for pediatric patients. SeaStar is classified as a smaller reporting company and an emerging growth company, which allows it to meet reduced disclosure requirements. Recent developments include a notice from Nasdaq about potential delisting due to failing to meet the minimum market value requirement, which they have until June 22, 2025, to comply with. This filing allows SeaStar to advance its capital strategy while addressing its operational and compliance challenges.

Form Type: CORRESP

Filing Date: 2025-04-25

Corporate Action: Ipo

Type: New

Accession Number: 000121390025035637

Filing Summary: SeaStar Medical Holding Corporation has filed a request for the acceleration of the effective date of their Registration Statement on Form S-3 (File No. 333-286677). The company requests that the Registration Statement become effective as of 5:00 p.m., Eastern Time, on April 29, 2025, or as soon thereafter as practicable. The filing is communicated to the United States Securities and Exchange Commission and seeks confirmation of the effective date orally through their counsel, Dorsey & Whitney LLP. The letter is signed by Eric Schlorff, Chief Executive Officer of SeaStar Medical Holding Corporation.

Form Type: 424B5

Filing Date: 2025-02-03

Corporate Action: Ipo

Type: New

Accession Number: 000121390025009443

Filing Summary: SeaStar Medical Holding Corporation is offering 713,000 shares of its common stock and Pre-Funded Warrants to purchase 2,816,412 shares of common stock to a single institutional investor. The offering price per share is $1.70, and the exercise price for each Pre-Funded Warrant is $1.699. The offering is intended to enhance capital for the company, which has developed a proprietary therapy platform to address hyperinflammation through its Selective Cytopheretic Device (SCD). The company has obtained regulatory approval for its pediatric SCD product 'QUELIMMUNE.' Additionally, the document states that there is an ongoing pivotal clinical trial for adult patients with acute kidney injury. The proceeds from this offering are estimated to be approximately $6 million before expenses, and the total expenses are expected to be around $500,000. The document discloses recent developments including a public reprimand from Nasdaq regarding a prior transaction which was determined to exceed 20% of the company's outstanding shares without sufficient shareholder approval. Furthermore, the summary notes the implications of being a smaller reporting company and the associated reduced disclosure requirements, alongside the plans for proceeds usage, which primarily focuses on development and commercialization activities.